Retatrutide is an investigational triple agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
By hour 24, most patients report complete symptom resolution or residual tenderness only with direct pressure
Hangngoainhap.com.vn/Jd
Other growth hormone secretagogue peptides (CJC-1295, ipamorelin, MK-677) work through similar but not identical mechanisms
During early phases of GLP-1 use, when weight loss may be faster, the risk of muscle loss is higher
Dogan ADA, Hess S, Jensen TT, Bladbjerg E-M, Juhl CB, Hilberg O